SETD3 and cancer: These data suggest that the NUDT16-SETD3 pathway may play critical roles in the induction of tolerance to radiotherapy and that targeting NUDT16 may be a promising strategy for reversing the resistance of cancer cells to IR therapy in clinical trials.